| Author | Nogueira, Renata Campos | |
| Author | Cerqueira, Harley Ferreira de | |
| Author | Soares, Milena Botelho Pereira | |
| Access date | 2019-02-14T17:07:15Z | |
| Available date | 2019-02-14T17:07:15Z | |
| Document date | 2010 | |
| Citation | NOGUEIRA, R. C.; CARQUEIRA, H. F.; SOARES, M. B. P. Patenting bioactive molecules from biodiversity: the Brazilian experience. Expert Opinion on Therapeutic Patents, v. 20, n. 2, p. 145-157, 2010. | pt_BR |
| ISSN | 1354-3776 | pt_BR |
| URI | https://www.arca.fiocruz.br/handle/icict/31651 | |
| Sponsorship | Fundação de Amparo a Pesquisa do
Estado da Bahia (FAPESB). MBP Soares holds a senior
researcher fellowship from the Brazilian National Council
of Research (CNPq). | pt_BR |
| Language | eng | pt_BR |
| Publisher | Taylor & Francis | pt_BR |
| Rights | open access | pt_BR |
| Subject in Portuguese | Biodiversidade | pt_BR |
| Subject in Portuguese | Legislação brasileira | pt_BR |
| Subject in Portuguese | Diversidade química | pt_BR |
| Subject in Portuguese | Desenvolvimento de medicamentos | pt_BR |
| Title | Patenting bioactive molecules from biodiversity: the Brazilian experience | pt_BR |
| Type | Article | pt_BR |
| DOI | 10.1517/13543770903555221 | |
| Abstract | The use of natural compounds from biodiversity, as well as ethnobotanical knowledge, for the development of new drugs is the gate leading to support the conservation of natural resources in developing countries. Recent technological advances and the development of new methods are revolutionizing the screening of natural products and offer a unique opportunity to replace natural products as major source of drug leads. Over the past decades, the Brazilian government established a legislation aiming to grant patent protection in all technological fields. The Convention on Biological Diversity, an international agreement that recognizes the sovereign rights of States over their natural resources, and the Brazilian legislation (Decreto n degree 2186-12/01) set for legislative, administrative or policy measures regarding the share of research and product development benefits could be the key for progress in issues related to rational employment of the Brazilian biodiversity and economy, but are far from being effective. Based on literature review, this article provides a brief description of the Brazilian legislation policy regarding intellectual property and biodiversity access, places natural drug discovery in context, analyzes patent cases and highlights critical key issues responsible for the drawback of the whole process that has a direct impact on industrial and research development, nature protection and benefit share with our society. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório de Engenharia Tecidual e Imunofarmacologia. Salvador, BA, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório de Engenharia Tecidual e Imunofarmacologia. Salvador, BA, Brasil. | pt_BR |
| Affilliation | Fundação Oswaldo Cruz. Centro de Pesquisas Gonçalo Moniz. Laboratório de Engenharia Tecidual e Imunofarmacologia. Salvador, BA, Brasil. | pt_BR |
| Subject | Biodiversity | pt_BR |
| Subject | Brazilian legislation | pt_BR |
| Subject | Chemical diversity | pt_BR |
| Subject | Drug development | pt_BR |
| xmlui.metadata.dc.subject.ods | 03 Saúde e Bem-Estar | |
| xmlui.metadata.dc.subject.ods | 10 Redução das desigualdades | |
| xmlui.metadata.dc.subject.ods | 15 Vida terrestre | |
